Watch More Highlights
Erin Grannan, PharmD, BCOP, of The University of Texas MD Anderson Cancer Center, discusses the latest updates from the SUMMIT trial that advanced practitioners need to be aware of. Researchers explored the promising combinations of neratinib plus fulvestrant plus trastuzumab, neratinib plus trastuzumab, as well as fulvestrant alone. The combination regimens appeared to benefit patients with hormone–receptor positive HER2-mutated metastatic breast cancer who have had prior exposure to CDK4/6 inhibitors, and those with HER2-mutated triple-negative disease (Abstract GS4-10).